- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07582796
Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.
A Randomized, Blinded, Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) (Adjuvanted) in Adults Aged 18 Years and Older.
연구 개요
상태
개입 / 치료
- 생물학적: Recombinant Respiratory Syncytial Virus Vaccine(CHO cell)(Adjuvanted)
- 생물학적: Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant)
- 생물학적: Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant)
- 생물학적: Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Adjuvanted)
- 생물학적: Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Low adjuvant)
- 생물학적: Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Blank adjuvant)
- 생물학적: Normal Saline
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Xue Zhao, Master
- 전화번호: 18168168075
- 이메일: zhaoxue@abbbio.com.cn
연구 장소
-
-
Sichuan
-
Zigong, Sichuan, 중국
- 모병
- Zigong Center for Disease Control and Prevention
-
연락하다:
- Xue Zhao, Master
- 전화번호: 18168168075
- 이메일: zhaoxue@abbbio.com.cn
-
수석 연구원:
- Ting Huang, Bachelor
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Males or females aged 18 years and older at the time of enrollment (aged 18 years and older for the phase I part; aged 60 years and older for the phase II part), who are able to provide legal proof of identity.
- Voluntarily agree to participate in the trial, able to fully understand and sign the informed consent form.
- Able to attend all scheduled follow-up visits and comply with the requirements of the clinical trial protocol to complete the study.
Female participants must meet the following criteria: In the phase I part, women of childbearing potential* must have a negative pregnancy test prior to enrollment and be willing to use effective contraceptive measures for 12 months after receiving the investigational vaccine; in the phase II part, only women of non-childbearing potential will be enrolled.
- Women of childbearing potential: Defined as females who have experienced menarche and have not yet entered menopause, unless permanently sterile, such as documented bilateral salpingectomy, bilateral oophorectomy, or hysterectomy; menopause is defined as amenorrhea for 12 consecutive months without other medical cause.
[Effective contraceptive measures include: oral contraceptives, injectable contraceptives, subdermal implants or hormonal patches, intrauterine device (IUD), sterilization surgery, abstinence (no sexual intercourse), male condoms, etc.; rhythm method, withdrawal, and emergency contraception are not considered effective contraceptive measures.]
- Axillary body temperature ≤ 37.0°C measured on site prior to vaccination on the day of vaccination.
Exclusion Criteria:
- Clinically significant laboratory abnormalities that, in the investigator's comprehensive judgment, preclude enrollment (applicable only to the phase I part).
- Pregnant or breastfeeding women.
- A clear diagnosis of RSV infection or a history of RSV infection-related respiratory disease within 6 months prior to vaccination.
- Use of immunoglobulins or/and any blood products or plasma derivatives within 3 months prior to vaccination, or planned use during the study.
- Treatment with immunomodulators (including immunosuppressants and immunostimulants) within 6 months prior to vaccination (e.g., long-term use of systemic glucocorticoids for ≥14 days at a dose of ≥2 mg/kg/day or ≥20 mg/day prednisone or equivalent) (excluding inhaled, intra-articular, and topical steroids).
- Administration or planned use of long-acting immunomodulatory drugs (e.g., infliximab) at any time during the study.
- A history of severe allergic reactions (e.g., anaphylactic shock, allergic laryngeal edema, Henoch-Schönlein purpura, thrombocytopenic purpura, Arthus reaction) following any previous vaccination or drug use, or a family history of severe allergies.
- Impaired immune function or a diagnosis of congenital or acquired immunodeficiency, or human immunodeficiency virus (HIV) infection.
- A personal or family history of convulsions, epilepsy, encephalopathy, psychiatric disorders, or neurological diseases (such as Guillain-Barré syndrome, Miller Fisher syndrome).
- A diagnosis of lymphoproliferative disease or malignant tumor within 5 years.
- Clinically significant electrocardiogram (ECG) abnormalities as determined by the investigator (applicable only to the phase I part).
- Previous vaccination with any licensed or investigational RSV vaccine prior to enrollment, or planned vaccination during the study.
- Receipt of any vaccine within 14 days prior to vaccination, or any live vaccine within 30 days prior to vaccination.
- An acute disease or an acute exacerbation of a chronic disease within 3 days prior to vaccination, or use of antipyretic, analgesic, or anti-allergy medications.
- Suspected or known alcohol abuse or alcohol dependence (referring to a drinking pattern that causes serious mental or physical health problems) or drug abuse.
- A history of thrombocytopenia or other coagulation disorders that may contraindicate intramuscular injection.
- Severe or unstable chronic diseases, including but not limited to cardiovascular diseases [e.g., hypertension uncontrolled by medication (on-site blood pressure measurement prior to vaccination: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg), coronary heart disease, myocarditis, pericarditis, atrial fibrillation], metabolic diseases (e.g., poorly controlled diabetes), hematological disorders (e.g., severe anemia, hemophilia), hepatic or renal diseases, digestive system diseases, respiratory system diseases (e.g., chronic obstructive pulmonary disease, active pulmonary tuberculosis, other severe respiratory diseases).
Note: For participants aged 60 years and older, those with pre-existing stable disease may be enrolled. This is defined as participants who may have underlying conditions such as hypertension or diabetes, provided that symptoms and signs are stable and medically controllable as assessed by the investigator prior to vaccination, and who have not required changes to the treatment/medication regimen or hospitalization due to the underlying condition within 3 months.
- A history of confirmed immune-mediated/autoimmune diseases (e.g., cold agglutinin hemolytic anemia, lymphadenopathy, eosinophilia, systemic lupus erythematosus, gout, hyperuricemia, acute disseminated encephalomyelitis, immune thrombocytopenia, autoimmune aplastic anemia, autoimmune neutropenia, autoimmune lymphoproliferative syndrome, thrombocytopenic purpura).
- Asplenia or functional asplenia, as well as any condition resulting in asplenia or splenectomy.
- Currently participating in or planning to participate in another clinical study involving investigational or unregistered products (drugs, vaccines, medical devices, etc.) during this study.
- Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in this clinical trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: 플라시보 그룹
|
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
|
실험적: Investigational Vaccine 1 (Low Dose) Group
|
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
|
실험적: Investigational Vaccine 2 (Low Dose) Group
|
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
|
실험적: Investigational Vaccine 1 Group
|
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
|
실험적: Investigational Vaccine 2 Group
|
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
|
실험적: Investigational Vaccine 3 Group
|
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
|
위약 비교기: Adjuvant Control Group
|
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of solicited (local and systemic) adverse events (AEs) within 14 days post-vaccination.
기간: Within 14 days post-vaccination.
|
Within 14 days post-vaccination.
|
|
|
Incidence of unsolicited AEs within 30 days post-vaccination.
기간: Within 30 days post-vaccination.
|
Within 30 days post-vaccination.
|
|
|
Incidence of clinically significant laboratory abnormalities(blood biochemistry, blood routine, coagulation function, urinalysis) on Day 3 post-vaccination, and incidence of clinically significant ECG abnormalities on Days 3, 14, and 30 post-vaccination.
기간: On Days 3, 14, and 30 post-vaccination
|
Applicable to Phase I only
|
On Days 3, 14, and 30 post-vaccination
|
|
Incidence of serious adverse events (SAEs) and adverse events of special interest (AESIs) within 12 months post-vaccination.
기간: Within 12 months post-vaccination.
|
Within 12 months post-vaccination.
|
|
|
At 1 month post-vaccination: geometric mean titer (GMT) of neutralizing antibodies against RSV-A and RSV-B.
기간: At 1 month post-vaccination
|
Applicable to Phase Ⅱ only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: seroresponse rate (SRR) of neutralizing antibodies against RSV-A and RSV-B.
기간: At 1 month post-vaccination
|
Applicable to Phase Ⅱ only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: geometric mean fold rise (GMFR) of neutralizing antibodies against RSV-A and RSV-B.
기간: At 1 month post-vaccination
|
Applicable to Phase Ⅱ only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: geometric mean concentration (GMC) of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
기간: At 1 month post-vaccination
|
Applicable to Phase Ⅱ only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
기간: At 1 month post-vaccination
|
Applicable to Phase Ⅱ only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
기간: At 1 month post-vaccination
|
Applicable to Phase Ⅱ only
|
At 1 month post-vaccination
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
At 1 month post-vaccination: GMT of neutralizing antibodies against RSV-A and RSV-B.
기간: At 1 month post-vaccination
|
Applicable to Phase I only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: SRR of neutralizing antibodies against RSV-A and RSV-B.
기간: At 1 month post-vaccination
|
Applicable to Phase I only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: GMFR of neutralizing antibodies against RSV-A and RSV-B.
기간: At 1 month post-vaccination
|
Applicable to Phase I only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: GMC of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
기간: At 1 month post-vaccination
|
Applicable to Phase I only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
기간: At 1 month post-vaccination
|
Applicable to Phase I only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
기간: At 1 month post-vaccination
|
Applicable to Phase I only
|
At 1 month post-vaccination
|
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMT of neutralizing antibodies against RSV-A and RSV-B.
기간: At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination: SRR of neutralizing antibodies against RSV-A and RSV-B.
기간: At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMFR of neutralizing antibodies against RSV-A and RSV-B.
기간: At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMC of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
기간: At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
기간: At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
기간: At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
|
At 14 days, 1 month, and 6 months post-vaccination: counts of CD4+ and CD8+ T cells expressing at least two activation markers (IFN-γ, IL-2, TNF-α, CD40L)
기간: At 14 days, 1 month, and 6 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 1 month, and 6 months post-vaccination
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Ting Huang, Bachelor, Sichuan Center for Disease Control and Prevention
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- aRSV-ZHSW-01
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .